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All known members of the p53 gene family, including
the two homologs p73 and p63, have multiple biologi-
cal functions. In neurons, p53 and p73 are known to
regulate cell death in the developing and adult ner-
vous system. A report by Jacobs et al. in this issue
of Neuron shows that the more ancestral member of
this gene family, p63, is an essential proapoptotic pro-
tein during neuronal development.
The transcription factor and tumor suppressor p53 and
its two recently described homologs, p63 and p73, form
a protein family whose members are endowed with re-
ciprocal regulatory functions (Melino et al., 2003). They
are expressed both as multiple alternatively spliced C-
terminal isoforms and as N-terminally deleted isoforms,
which—along with posttranslational modifications—
accounts for their molecular and regulatory complexity.
All three major p53 family members are transcription fac-
tors, with a modular structure (Figure 1A), which com-
prises transactivation (TA), DNA-binding (DBD), and olig-
omerization (OD) domains, which are essential for their
downstream effects, including cell-cycle arrest and apo-
ptosis. In addition to C-terminal splicing, which gives rise
to isoforms not discussed here, all three members of the
family can also be transcribed starting from a second
downstream promoter. This generates N-terminally trun-
cated (DN) isoforms that lack the TA domain (full-length
proteins are denominated as TA isoforms). The DN iso-
forms can act as dominant-negative inhibitors of the TA
isoforms and of p53. Thus, TA andDN have pro- and anti-
apoptotic properties, respectively. The ancestor of this
protein family, p63 (Yang et al., 1998), has a very high
degree of sequence homology with p73, which is known
to play an important role in controlling neuronal develop-
ment. The 86% identity (92% similarity) in the DNA-
binding domains suggests that p63 and p73 may target
overlapping promoters in those tissues where their de-
gree of expression is similar. Interestingly, although all
p53/p63/p73 family members regulate both cell cycle
and apoptosis, developmental abnormalities are most
prominent in the p73 and p63 null mice. Mice deficient
in all p73 isoforms exhibit profound defects, including
hippocampal dysgenesis, hydrocephalus, chronic infec-
tions, and inflammation, as well as abnormalities in pher-
omone sensory pathways. Deletion of p63 results in se-
vere limb truncations, craniofacial malformations, and,
most important, the absence of skin and most epithelial
tissues as well as defective epidermal differentiation
(Yang et al., 1999; Mills et al., 1999). In contrast, p532/2
mice do not display major developmental defects. This
suggests that while the evolutionarily older family mem-
bers may primarily function in developmental regulation,
the younger member of the family, p53, has a more rele-
vant role in the response to DNA damage (Figure 1B).
Neuronal developmental death is required to eliminate
redundancies in connecting neuronal networks. In sym-pathetic neurons, signaling via the TrkA/NGF and
p75NTR receptors by target-derived neurotrophins is
essential for survival, and lack of this stimulation results
in apoptosis. The signaling cascade, involving JNK,
c-Jun, BimEL, and Bax, has not yet been completely elu-
cidated. The p53 protein family has been implicated in
the death signaling following NGF withdrawal. Initially,
a suggestion had been made that the balance between
the proapoptotic function of p53 and the prosurvival
function of DNp73 (attributed to its dominant-negative
function on p53) could be a factor deciding the fate of
cultured sympathetic neurons deprived of neurotrophin
stimulation (Pozniak et al., 2000). However, several other
findings have indicated that p53 is not the only proapo-
ptotic effector in sympathetic neurons: p53 null neurons
are only partially protected from NGF withdrawal and, in
p732/2 mice, the absence of p53 rescues neurons only
in part. Finally, p532/2 mice have only a partial deficit
in sympathetic neuronal death.
In this issue of Neuron, Jacobs and colleagues
(Jacobs et al., 2005) find a more convincing solution to
the saga of the p53 gene family and its involvement in
developmental neuronal death. They reveal an unex-
pected and essential role of TAp63g in naturally occur-
ring sympathetic neuronal death (Figure 1C). Developing
sympathetic neurons express TAp63g at the time of de-
velopmental death, and most importantly, the TAp63g
level increases upon NGF withdrawal. Adenoviral ex-
pression of p63g induces apoptosis even in the pres-
ence of NGF, and finally, embryonic p632/2mice display
a deficit in naturally occurring developmental neuronal
death. Moreover, while both p63 and p53 transactivate
Bax to induce cell death, TAp63 can trigger neuronal
apoptosis in the absence of p53, whereas p53 requires
coincident p63 expression. Altogether these findings
strongly support the central role of TAp63g in sympa-
thetic neuronal development, which can be explained
by its proapoptotic function. Bax expression is required
for TAp63g-induced neuronal death in analogy with
TAp73 and p53 and with TAp63a. Interestingly, in a re-
cent study by Gressner and colleagues (Gressner et al.,
2005), it was found that TAp63 can mediate apoptosis
triggered via death receptor complexes (CD95, TRAIL,
TNF, FLIP) as well as that involving primarily the mito-
chondrial (Bax, Noxa, Puma, Apaf-1) death pathway.
This places p63 on both apoptotic routes and suggests
that TAp63g may behave in a similar manner in sympa-
thetic neurons. Because Bax is downstream of JNK in
sympathetic neuronal death, TAp63g acts between JNK
signaling and the effector Bax (Figure 1C). Neuronal de-
mise triggered by a variety of conditions including brain
ischemia and b-amyloid neurotoxicity seems to require
the signaling cascade involving JNK, BH3-only Bcl-2
family members, and Bax. Also, a large body of literature
has investigated the possible role of p53, and more
recently of p73, in neuronal death. In view of the find-
ing presented here, it would be interesting to explore
whether p63 may also have a dominant role in postnatal
neuronal demise nested in the JNK-Bax route and inde-
pendently of p53.
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(A) General domain structure of the p53, p73,
p63 proteins. The gene contains two pro-
moters, codifying for a full-length protein, in-
dicated as TA isoforms, and a shorter protein
coded by the second promoter, lacking the
TA domain, indicated asDN isoforms. In addi-
tion, extensive mRNA splicing occurs at the
30 end, resulting in several protein isoforms,
shown as dashed block. The residue identity
is indicated in red for each domain. The most
closely related proteins are p63 and p73. TA,
transactivation domain; DBD, DNA-binding
domain; PR, proline-rich domain; SAM, sterile
a motif; TI, transactivation inhibitory domain.
(B) Schematic function of the p53 family pro-
teins. The functions span from development
to DNA damage; this seems to reflect the on-
togeny of the proteins, with p63 being the
most evolutionarily ancient and p53 the most
recent.
(C) The ‘‘Route p63’’ in sympathetic neuronal
death.Along these lines, of particular importance is finding
that the proapoptotic role of TAp63g in sympathetic
neurons does not require p53. In fact, p53 requires
TAp63 to fulfill its death mission. Thus, the function of
the antiapoptotic protein DNp73 in sympathetic devel-
opment reported earlier can be explained by its regula-
tion of TAp63 rather than its ability to neutralize p53
proapoptotic function (see scheme in Figure 1C). In-
deed, p632/2 sympathetic neurons are resistant to de-
velopmental cell death both in vitro and in vivo. The
coincident requirement of p73 and p63 to selectively
activate proapoptotic molecules such as Noxa, Perp,
and Bax initially shown by Flores and colleagues (Flores
et al., 2002) suggests that a close cooperation between
the two molecules is required to trigger apoptosis, at
least in some tissues. Surprisingly, cells of mice deficient
in both p63 and p73 exhibit a significant resistance to
neuronal apoptosis induced by cisplatin or g-radiation,
despite the presence of functionally competent p53.
This suggests that p53 may be upstream of TAp73 and
TAp63 in the apoptotic pathway, and it is unable to trig-
ger cell death in the absence of its siblings. The litera-
ture, which has investigated the involvement of p53 in
different forms of neuronal demise, should perhaps be
revisited in light of the findings presented here. Clearly,
the suggestion that TAp63 could be the effector of
the p53 proapoptotic function raises crucial queries.
What is the molecular basis of this apparently incestu-
ous relationship? Is the DNp63 dominant-negative loop
involved? How are different members of the family
recruited/upregulated to selectively transactivate target
genes? Does the p53 and p63, p73 partnership have fun-
damentally different biological implications than those
caused by selective expression of the individual genes?
The function and expression level of p63 and the other
family members can obviously be regulated by several
factors, including selective induction, but also post-
translational modifications, including phosphorylation,
control of protein stability, and regulation by other pro-
teins (Figure 2A). Most of what is currently known about
p63 regulation comes from studies in nonneuronal tis-sues. p63 transcriptional activity is complex and re-
quires a specific spatial localization as well as the inter-
action with other non-family member proteins, such as
the promyelocytic leukemia protein (PML), which physi-
cally interacts with the p63 protein and determines the
p63 localization into the PML Nuclear-Bodies (PML-
NBs) (Bernassola et al., 2005). This interaction between
p63 and PML increases the steady-state protein levels
of p63 in cultured cells and p63 transcriptional activation
of Bax and cell cycle-related genes such as gadd45 and
p21. PML bodies are found in healthy neurons but also in
pathological settings. Their assembly is particularly evi-
dent in disease states (i.e., in the reactive sensory gan-
glion neurons of the Guillain-Barre syndrome, in amyo-
trophic lateral sclerosis, and possibly in intranuclear
inclusion disease). The function of p63 is also modulated
by phosphorylation and prolyl-isomerization by Pin-1
(G.M., unpublished data). PML regulation and posttrans-
lational modifications are essentially similar for all p53
family members and indicate that p63 follows the strict
sequence of activation control described for its siblings
(see Figure 2B).
From biblical times, our culture is populated by the
antagonism of life and death, good and evil, and often
these dichotomies run in close families. Like Cain and
Abel, Romulus and Remus, and countless others, the
members of the p53 family play dangerously one against
the other in a game of death and survival. But is it as sim-
ple as ‘‘live and let die’’? Or is there a possibility that the
members of this family may entertain more subtle inter-
actions? According to Jacobs and colleagues (Jacobs
et al., 2005), TAp63 regulates neuronal development
primarily by acting through the cell death machinery.
This is consistent with the evidence that NGF withdrawal
primarily promotes cell death. However, in nonneuronal
settings (i.e., epidermal biology) there is substantial
evidence that p63 controls differentiation (according to
Dennis Roop and colleagues; Mills et al., 1999) or the
stem cell compartment (according to Frank McKeon
and colleagues; Yang et al., 1999) (see Figure 2C). Al-
though the epidermal p632/2 phenotype reported by
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(A) Degradation and transactivation pathways
of the p63 protein. The transactivation func-
tion of p63 depends on its steady-state pro-
tein levels, controlled transcriptionally and
by yet unkown degradation pathways, and it
is strictly regulated by a series of mechanisms
involving phosphorylation, prolyl isomeriza-
tion by Pin-1, PML recruitment in the PML-
nuclear bodies, and acetylation.
(B) Schematic molecular mechanism of the
transactivation pathways valid for the p53/
p73/p63 proteins.
(C) The developmental effects of p63 could
be due to failure to differentiate (according to
Dennis Roop), failure to regulate the prolifera-
tion potential of the stem cell compartment
(according toFrankMcKeon),or failure tocon-
trol apoptosis (according to David Kaplan).the two independent laboratories was identical, the in-
terpretation of the underlying mechanism responsible
for the p63 null phenotype remains in sharp contrast.
While Roop and Bradley conclude that p63 controls epi-
dermal differentiation, McKeon suggests that differenti-
ation of the epidermis remains normal, whereas the p63
defect influences the proliferation potential of the stem
cell compartment (see Figure 2C). It is clear that both
TAp63 and DNp63 control the transcriptional activation
or derepression of many genes involved in signaling and
development, in addition to apoptosis. For example, the
phosphoinoside-3-kinase pathway can regulate p63
downstream of the epidermal growth factor receptor
(Barbieri et al., 2003), which links p63 to the PTEN path-
way. Furthermore, p63 can physically interact with its
own family members, can induce b-catenin accumula-
tion with subsequent gene regulation (Patturajan et al.,
2002), and can regulate the redox balance through
REDD1 (Ellisen et al., 2002). Finally and most relevant
in neurons, p63 can regulate the c-fos proto-oncogene,
two ligands of Notch, JAG1 and JAG2, and the Wnt path-
way gene hDKK1 (Wu et al., 2003). These are obviously
all crucial for neural function and development. In addi-
tion, p73 has direct effects on neuronal development,
unrelated to cell death (De Laurenzi et al., 2000; Billion
et al., 2004).
The work by Jacobs and colleagues highlights a new
dimension in the complicated network of the p53 gene
family and its role in neuronal development. Clearly, as
new horizons are opened by these observations, many
exciting questions still lie ahead. The understanding of
the role of these proteins in responding to external
cues (or lack thereof), versus internal cell-autonomous
signals to differentiation, will likely be one of the most
challenging.
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